Last reviewed · How we verify
Normothermic ex-vivo kidney perfusion Solution -Toronto
Normothermic ex-vivo kidney perfusion Solution -Toronto is a Small molecule drug developed by University Health Network, Toronto. It is currently in Phase 1 development.
At a glance
| Generic name | Normothermic ex-vivo kidney perfusion Solution -Toronto |
|---|---|
| Sponsor | University Health Network, Toronto |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Normothermic ex-vivo kidney perfusion Solution -Toronto CI brief — competitive landscape report
- Normothermic ex-vivo kidney perfusion Solution -Toronto updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI
Frequently asked questions about Normothermic ex-vivo kidney perfusion Solution -Toronto
What is Normothermic ex-vivo kidney perfusion Solution -Toronto?
Normothermic ex-vivo kidney perfusion Solution -Toronto is a Small molecule drug developed by University Health Network, Toronto.
Who makes Normothermic ex-vivo kidney perfusion Solution -Toronto?
Normothermic ex-vivo kidney perfusion Solution -Toronto is developed by University Health Network, Toronto (see full University Health Network, Toronto pipeline at /company/university-health-network-toronto).
What development phase is Normothermic ex-vivo kidney perfusion Solution -Toronto in?
Normothermic ex-vivo kidney perfusion Solution -Toronto is in Phase 1.